Limited Time Offer · Plans from $145/mo*

Provider Comparisons

6 min read

Fig treatments are prescribed by board-certified physicians after an individual medical review.

Wegovy vs. Compounded Semaglutide: Understanding Your Weight Loss Options

Quick answer: Wegovy is an FDA-approved semaglutide product indicated for weight management, while compounded semaglutide is prepared by licensed 503A pharmacies and is not FDA-approved. They are not the same product and compounded versions are not substitutes. Cost and access are usually the deciding factors for patients paying without insurance.

Check my eligibility →

Medical Disclaimer: The information provided in this article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment. Individual results may vary.

Introduction

For individuals seeking effective weight management solutions, GLP-1 receptor agonists have emerged as a significant advancement. Among these, semaglutide, available as brand-name medications like Wegovy and in compounded forms, offers a powerful approach to weight loss. This article will delve into the key differences and similarities between Wegovy and compounded semaglutide to help you make an informed decision.

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of the natural GLP-1 hormone, which plays a crucial role in appetite regulation and glucose metabolism. By activating GLP-1 receptors, semaglutide helps to:

Reduce appetite and food cravings
Slow gastric emptying, promoting a feeling of fullness
Improve insulin secretion in a glucose-dependent manner
Decrease glucagon secretion

These combined effects lead to reduced calorie intake and significant weight loss.

Wegovy: The FDA-Approved Option

Wegovy is an FDA-approved, brand-name injectable medication containing semaglutide, specifically indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [1]. Its approval is based on extensive clinical trials, such as the STEP (Semaglutide Treatment Effect in People with Obesity) program, which demonstrated its efficacy and safety [2]. For instance, in the STEP 1 trial, participants receiving semaglutide 2.4 mg achieved an average weight loss of approximately 15% over 68 weeks [3].

Key Features of Wegovy:

FDA-Approved: Undergoes rigorous testing for safety, efficacy, and manufacturing quality [1].
Standardized Formulation: Consistent dosage and purity.
Clinical Evidence: Supported by large-scale clinical trials, demonstrating significant and sustained weight loss [2, 3].

Compounded Semaglutide: An Alternative Approach

Compounded semaglutide refers to medications prepared by compounding pharmacies. These pharmacies combine or alter ingredients to create a medication tailored to an individual patient's needs, often when a commercial drug is unavailable or unsuitable. In the context of semaglutide, compounding typically occurs during drug shortages or when patients have specific allergies to inactive ingredients in brand-name versions.

Important Considerations for Compounded Semaglutide:

Not FDA-Approved: Compounded medications do not undergo the same FDA approval process for safety, efficacy, and manufacturing as brand-name drugs. The FDA has expressed concerns about the safety and effectiveness of compounded semaglutide products, noting that they have not been reviewed for safety, effectiveness, and quality [4, 5].
Regulatory Oversight: While compounding pharmacies are regulated by state boards of pharmacy and the FDA, the oversight differs from that of pharmaceutical manufacturers. The FDA has clarified that certain conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act [6].
Ingredients: Compounded semaglutide may sometimes include additional ingredients, such as B vitamins (e.g., cyanocobalamin or pyridoxine), which are not part of the FDA-approved formulation of Wegovy.

Wegovy vs. Compounded Semaglutide: A Comparison

Feature Wegovy Compounded Semaglutide FDA Approval Yes, for chronic weight management [1] No, not FDA-approved [4, 5] Formulation Standardized, consistent purity and dosage Variable, quality and purity can differ Clinical Trials Extensive, large-scale studies (e.g., STEP) [2, 3] Limited or no specific clinical trials for compounded versions Availability Subject to supply chain and insurance coverage Often available during shortages or for specific patient needs Additional Ingredients Semaglutide only May contain additional ingredients (e.g., B vitamins) Cost Can be high, varies with insurance coverage Often lower, but transparency can vary

Fig Health: Transparent and Affordable GLP-1 Options

At Fig Health, we believe in making effective weight loss solutions accessible and transparent. We offer medically supervised GLP-1 programs with clear pricing and no hidden fees. Our focus is on providing high-quality care and support throughout your weight loss journey.

Ready to start your weight loss journey with Fig Health?

Click here to start your online visit today!

Fig's Transparent Pricing:

Membership Fee: $0
Compounded Semaglutide: $145-$175/month
Compounded Tirzepatide: $258-$279/month

Conclusion

Both Wegovy and compounded semaglutide offer pathways to weight loss through the action of GLP-1. However, understanding the critical differences in FDA approval, formulation consistency, and regulatory oversight is paramount. While Wegovy provides an FDA-approved, clinically proven option, compounded semaglutide can be an alternative under specific circumstances, though it comes with varying quality and regulatory scrutiny.

Keep reading

Also helpful: Mounjaro vs. Compounded Tirzepatide: Cost, Access, and What to Know

Wondering whether GLP-1 treatment could be right for you? Take the free assessment to see if you qualify.

References

[1] U.S. Food and Drug Administration. Wegovy (semaglutide) injection. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
[2] Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3] NovoMedLink. Chronic Weight Management Trial Results | Wegovy. Available at: https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html
[4] U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Available at: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[5] NovoMedLink. Compounded "semaglutide" is not FDA-approved. Available at: https://www.novomedlink.com/semaglutide/patient-safety/difference-fda-approved-compounded-semaglutide.html
[6] U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Available at: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

See if you qualify in about 2 minutes

Free online assessment. No charge unless you are approved.

Take the quiz — free